Preclinical discovery and profiling

Attrition Reducing Technologies (ART):

• ART-one: high throughput (200-500 compounds/week) in vitro assay and in silico prediction of key ADME and pharmaceutical properties (e.g. solubility, metabolic stability, permeability)
• ART-two: assessment of pre-clinical liabilities potentially critical for clinical development (e.g. cross-species intrinsic clearance and protein binding, in vitro cytotoxicity, formation of reactive metabolites, drug-drug interaction potential)
• ART-three: pre-clinical investigations to support lead optimization and drug candidate selection, including:
  • virtual screening and in silico predictions, PB/PK modeling
  • in vitro safety, genotoxicity and teratogenicity (DART)
  • in vitro metabolism, including reaction phenotyping, isolated perfused liver

Safety pharmacology

• In silico/in vitro/in vivo safety pharmacology to assess cardiovascular liabilities, including effect on QT intervals

Experimental ADMET

• Single or repeated dose studies in different animal species to assess:
  • pharmacokinetics (PK) and bioavailability,
  • target organ toxicity,
  • pharmacokinetics/Pharmacodynamics (PK/PD).